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Abstract
There is a paucity of chemotherapy options for patients with urothelial cancers who have relapsed following platinum based 
chemotherapy (CT). 
CAB-B1 was a single centre phase II randomised controlled trial of Cabazitaxel (CAB; 25mg/m2 q3 week for 6 cycles) versus 
best supportive care (BSC) in patients with histologically proven transitional cell carcinoma (TCC), locally advanced or 
metastatic, who had recurred after receiving platinum based treatment. Primary outcome was overall response rate (ORR) 
using RESIST. Secondary outcomes included Progression Free Survival (PFS) and Overall Survival (OS). 
Between January 2013 and October 2016, 20 patients were randomised (10 on each arm). BSC included paclitaxel CT for 9 
patients and radiotherapy for 1 patient. 8 patients completed 6 cycles of CT (3 on CAB; 5 on BSC). 2 patients had an ORR 
on CAB and 1 patient on BSC. Median OS was 5.8 months (95% confidence interval (CI) 0.7-14.6) for CAB patients and 
7.5 months (95% CI 1.0-10.8) for BSC patients. Median PFS was 4.8 months (95% CI 0.7-8.3) for CAB patients and 3.7 
months (95% CI 1.0-7.0) for BSC patients. 
CAB-B1 successfully reached the efficacy target for 1st stage, showing that there could be a role for CAB in these patients. 
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Introduction
Bladder cancer is the 10th most common cause of cancer in the UK 
[1]. The majority of bladder tumours occur in men, where it is the 
6th most common cause of cancer and 12th most common cause of 
cancer death in females [1]. The survival of untreated metastatic 
patients does not exceed 3 to 6 months, and systemic chemotherapy 
increases overall survival of patients with unresectable disease 
[2,3,4]. However, the overall survival (OS) of patients with advanced 
disease treated with chemotherapy remains short (about 14 months) 
and new agents are needed in this very poor prognosis disease. 
There was no standard of care for patients who relapsed after 
previously receiving neo-adjuvant chemotherapy and there was 
no standard second line chemotherapy at the time this study was 
planned.
Cabazitaxel (Jevtana), a semisynthetic compound derived from 
European yew needles demonstrated activity in cell lines with 
acquired resistance to doxorubicin, vincristine, vinblastine, 
paclitaxel, and docetaxel. Cabazitaxel is standard of care in treatment 
of metastatic prostate cancer following Docetaxel failure [5].
This phase II study was designed to see whether Cabazitaxel had 
activity in relapsed patients with transitional cell carcinoma (TCC) 
compared to best supportive care (BSC) (including single agent 
chemotherapy). Paclitaxel was used as chemotherapy of choice in 
BSC arm as it showed some activity in advanced urothelial cancers 
with known safety profile [6,7].
Methods
CAB-B1 was a single centre open labelled phase II randomised 
controlled trial of Cabazitaxel versus BSC in patients with 
histologically proven TCC, locally advanced (T4b) or metastatic 
(lymph node or visceral), who had recurred after receiving platinum 
based treatment. Eligible patients were aged 18 or above with an 
Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 or 1 and a life expectancy of 12 weeks or more. All patients 
gave written informed consent. Patients were excluded if they had 
been treated previously with a taxane, had inadequate organ and 
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bone marrow function, history of inflammatory bowel disease or had 
any of the following events within 6 months prior to randomisation: 
myocardial infarction, severe/unstable angina, coronary/peripheral 
artery bypass graft surgery, clinically symptomatic and uncontrolled 
cardiovascular disease, or clinically significant arrhythmias (grade 
3-4). 
Eligible patients were randomised centrally on a 1:1 basis using 
block randomisation with variable block sizes. Randomisation was 
stratified by the time from last chemotherapy cycle to recurrence 
(<6 months; >=6 months).
 
The patients randomised to the Cabazitaxel arm, received 25 to 20 
mg/m², administered by IV route, 3 week cycle with maximum of 6 
cycles. IV premedication including an antihistamine, corticosteroid, 
H2 antagonist was given. Primary prophylaxis with Granulocyte 
Colony Stimulating Factor (G-CSF) was given in patients with 
high-risk clinical features such as; age > 65 years, poor performance 
status, previous episodes of febrile neutropenia, extensive prior 
radiation ports, poor nutritional status, or other serious comorbidities 
that predispose them to increased complications from prolonged 
neutropenia. 
BSC was administered according to institutional standards (including 
6 cycles of single agent chemotherapy, palliative radiotherapy, 
antibiotics, analgesics, corticosteroids, and transfusion).
Clinical examinations including weight, ECOG performance 
status, laboratory tests (including complete blood counts, and 
serum chemistry) and adverse events (NCI CTCAE v.4.03) were 
obtained prior to drug administration, every cycle before treatment 
administration and up to 30 days after the last study treatment 
administration. Treatment response was assessed by computerized 
tomography (CT) of the whole body (chest, abdomen, and pelvis) 
at baseline and following cycles 3 and 6 (end of treatment scan) 
of chemotherapy and whenever disease progression is suspected. 
Patients completed the Euro QOL EQ-5D at baseline, and every 
cycle before treatment administration and at the post treatment visit. 
Patients were followed every 3 months until death or withdrawal of 
consent to participate in the study.
The primary outcome was overall response rate (ORR) using the 
Response Evaluation Criteria in Solid Tumours (RECIST) criteria. 
Secondary outcomes were Progression Free Survival (PFS), OS, 
Quality of Life assessment, safety and tolerability. 
A total of 96 patients (48 patients on each arm) were required to 
detect differences in ORR from 5% in the BSC arm to 30% in the 
Cabazitaxel arm with 80% power, a 5% two-sided significance level 
and allowing for 10% dropouts. Stopping rules were calculated based 
on the Simon’s two stage optimal design to assess the individual 
effectiveness of Cabazitaxel assuming the lower ORR limit for an 
ineffective drug at 0.05 and the target ORR for an effective drug 
at 0.20, With 80% power and a 5% two sided significance level, at 
least 1 ORR was required from 10 patients on Cabazitaxel at the 
first stage and 4 ORR from 29 patients on Cabazitaxel at the second 
stage. An interim analysis was performed after 20 patients in total 
were recruited into the first stage. However, due to slow recruitment 
the trial closed after the first stage.
Descriptive statistics with associated 95% confidence intervals 
(CI) are presented; due to the small numbers of patients no formal 
statistical tests are performed. OS was calculated as the time from 
the date of trial entry until the date of death or censored at the 
date last known to be alive. PFS was calculated as the time from 
the date of trial entry until the date of documented progression or 
date of death from any cause or censored at the date last known to 
be alive and progression free. Kaplan-Meier survival curves were 
constructed for OS and PFS. A Cox proportional hazards model 
was fitted to obtain a hazard ratio and associated 95% CI for the 
treatment effect. Quality of life data from the EQ-5D was analysed 
by a standardised area-under-the-curve analysis. The worst grade 
experienced by each patient for each CTCAE category is reported. 
All analyses are performed on an intention-to-treat basis using the 
SAS statistical software (version 9.4). 
The trial is registered as an International Standardised Randomised 
Controlled trial, number ISRCTN76947550. The trial was carried 
out in accordance with the Declaration of Helsinki and approved 
by research ethics committee and regulatory authorities.
Results
Between January 2013 and October 2016, 47 patients were screened 
for eligibility; 27 were excluded as they were either not eligible 
or declined to take part (Figure 1). A total of 20 patients were 
randomised (10 on each arm). Patient characteristics were similar 
across trial arms (Table 1): 75% were males; median age 68 years; 
65% had recurred within 6 months of previous CT. 
Figure 1: CONSORT diagram
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Table 1: Patient baseline characteristics
Characteristic Cabazitaxel Best supportive care Total
n % n % n %
10 50 10 50 20
Gender
Male 7 70 8 80 15 75
Female 3 30 2 20 5 25
Age years (Median(Range)) 70 (41-77) 69 (57-83) 70 (41-83)
Site of origin
Bladder 8 80 9 90 17 85
Upper tract 2 20 1 10 3 15
Pathology
Transitional Cell Carcinoma (TCC) 8 80 10 100 18 90
Mixed pathology with predominately 
TCC
2 20 0 0 2 10
Disease stage
Locally advanced (T4b) 1 10 0 0 1 5
Metastatic TCC 9 90 10 100 19 95
Time between last dose of chemotherapy and recurrence
< 6 months 6 60 7 70 13 65
>= 6 months 4 40 3 30 7 35
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Of the 10 patients randomised to Cabazitaxel, 1 patient did not start 
treatment as had raised ALT and only 3 (30%) patients completed 
all 6 cycles of treatment. A total of 30 Cabazitaxel cycles were 
administered. Six patients discontinued Cabazitaxel early due to 
adverse events (neutropenic sepsis; pyelonephritis; acute kidney 
disease, abdominal pain and haematuria; fatigue and raised ALTs). 
One patient stopped treatment early due to disease progression.
Of the 10 patients that randomised to BSC, 9 patients were prescribed 
paclitaxel chemotherapy and one patient prescribed radiotherapy 
but died after one fraction. The 9 patients completed 37 cycles of 
paclitaxel chemotherapy, with 5 (56%) completing all 6 cycles of 
chemotherapy. The reasons for stopping chemotherapy were due to 
increased creatinine (n=1), disease progression (n=1), death (n=1) 
and withdrawing consent (n=1). 
Only 3 (5%) cycles of the 67 cycles administered were delayed 
(2 out of 30 (7%) on Cabazitaxel arm and 1 out of 37 (3%) on 
the BSC arm), due to requiring a blood transfusion, awaiting 
results of scan or patient choice. A total of 6 (9%) of the 67 cycles 
administered involved dose alterations (5 cycles out of 30 (17%)) 
for 3 patients on Cabazitaxel arm and 1 out of 37 (3%) on the BSC 
arm), predominately due to clinical decision or toxicity. 
Ten serious adverse events (SAEs) were experienced by 6 patients 
on the Cabazitaxel arm due to adverse events within the following 
system organ classes: gastrointestinal, renal and urinary, infections 
and metabolic and nutrition that resulted in hospitalisation. Three 
patients on the best supported care arm experienced 5 SAEs due to 
adverse events (renal and urinary, and infections) that resulted in 
hospitalisation. The worst grade for any adverse event experienced 
was grade 4 for two patients on Cabazitaxel; one patient experienced 
grade 4 thrombocytopena and one patient had grade 4 neutropenic 
sepsis and deteriorated renal function. Grade 3 adverse events were 
experienced for 5 patients on each arm. The adverse events that was 
most experienced were from the CTCAE categories blood and bone 
marrow (e.g. anaemia), metabolic/laboratory (e.g. raised creatinine) 
and gastrointestinal (e.g. nausea and constipation) (Table 2). 
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Table 2: Adverse events: Worst grade experienced
N(%) Cabazitaxel Best supportive care
Grade 0 1 2 3 4 0 1 2 3 4
Worst grade experienced 1 (10) 0 2 (20) 5 (50) 2 (20) 0 2 (20) 3 (30) 5(50) 0
CTCAE categorisations
Auditory/ear 10 (100) 0 0 0 0 9 (90) 1(10) 0 0 0
Blood/bone marrow 1 (10) 3 (30) 1 (10) 4 (40) 1 (10) 0 6 (60) 2 (20) 2 (20) 0
Constitutional symptoms 4 (40) 4 (40) 1 (10) 1 (10) 0 5 (50) 3 (30) 0 2 (20) 0
Dermatology/skin  6 (60) 4 (40) 0 0 0 4 (40) 3 (30) 3 (30) 0 0
Gastrointestinal 2 (20) 1 (10) 4 (40) 3(30) 0 3 (30) 3 (30) 4 (40) 0 0
Hemorrhage/
bleeding  10 (100) 0 0 0 0 9 (90) 1 (10) 0 0 0
Infection 7 (70) 0 1(10) 1(10) 1(10) 7 (70) 0 1(10) 2(20) 0
Lymphatics  9 (90) 1 (10) 0 0 0 9 (90) 1 (10) 0 0 0
Metabolic/
laboratory 3 (30) 2 (20) 4 (40) 1 (10) 0 5 (50) 4(40) 0 1 (10) 0
Neurology  8 (80) 2(20) 0 0 0 5 (50) 3(30) 1 (10) 1 (10) 0
Pain 7 (70) 1 (10) 1 (10) 1 (10) 0 5 (50) 0 4 (40) 1 (10) 0
Pulmonary/upper respiratory 8 (80) 1 (10) 0 1 (10) 0 8 (80) 2 (20) 0 0 0
Renal/
Genitourinary 5 (50) 2 (20) 1 (10) 1 (10) 1 (10) 6 (60) 3 (30) 1 (10) 0 0
Sexual/reproductive function 10 (100) 0 0 0 0 9 (90) 1 (10) 0 0 0
Twelve patients were evaluated for radiological response (six on each arm; Table 3). One patient had the 3 months scan after 2 cycles 
instead of 3 cycles. Four patients on each arm were not evaluated for response, as either the patient died of progression within 3 months (2 
on Cabazitaxel arm, 3 on BSC arm) or the patients stopped treatment after 1 cycle and did not go on to have the CT scan and be assessed 
for response (2 patients on Cabazitaxel; 2 on BSC). Two patients (20%) on the Cabazitaxel arm had a partial response; one patient had a 
partial response after 3 months but subsequently progressed by the 6 month assessment and one had stable disease at 3 months and then 
a partial response at 6 months. One (10%) patient on BSC arm had a partial response at 3 months but subsequently progressed by the 6 
month assessment. Thus the ORR was 2 (20%) patients on Cabazitaxel and 1 (10%) patient on BSC.
Table 3: Response to treatment
Characteristic Cabazitaxel Best supportive care Total
n % n % n %
10 10 20
Response at 3 months
Complete response (CR) 0 0 0 0 0 0
Partial response (PR) 1 10 1 10 2 10
Stable disease (SD) 3 30 4 40 7 35
Progressive disease (PD) 2 20 1 10 3 15
Not evaluated for response 4 40 4 40 8 40
Response at 6 months
Complete response (CR) 0 0 0 0 0 0
Partial response (PR) 1 10 0 0 1 5
Stable disease (SD) 1 10 3 30 4 20
Progressive disease (PD) 1 10 2 20 3 15
Not evaluated for response 7 70 5 50 12 60
Overall best response
Complete response (CR) 0 0 0 0 0 0
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Partial response (PR) 2 20 1 10 3 15
Stable disease (SD) 2 20 4 40 6 30
Progressive disease (PD) 2 20 1 10 3 15
Not evaluated for response 4 40 4 40 8 40
Seventeen patients are known to have died of their disease 9 patients 
on the Cabazitaxel arm; 8 on BSC arm). Three patients (1 patient 
on the Cabazitaxel arm; 2 on BSC arm) are still alive and have 
been followed up between 13.0 and 19.6 months. All patients have 
progressed. The median overall survival was 5.8 months (95% 
confidence interval (CI) 0.7-14.6) for Cabazitaxel patients and 7.5 
months (95% CI 1.0-10.8) for BSC patients (hazard ratio 1.06 (95% 
0.40-2.78), Figure 2). Median progression free survival was 4.8 
months (95% CI 0.7-8.3) for Cabazitaxel patients and 3.7 months 
(95% CI 1.0-7.0) for BSC patients (hazard ratio 0.71 (95% CI 0.29-
1.77), Figure 3).
Figure 2: Overall survival
Figure 3: Progression free survival
The median area under a curve using the EQ5D health today scores 
for those on Cabazitaxel was 71 (IQR 59-83, range 44-89) and 
77 (IQR 73-89, range 32-91) for those on BSC (Figure 4). The 
median area under a curve using the EQ5D utility scores for those 
on Cabazitaxel was 0.72 (IQR 0.59-0.77, range 0.34-0.92) and 0.76 
(IQR 0.71-0.89, range 0.64-0.91) for those on BSC.
Discussion
Muscle invasive bladder cancer treatment options remain limited 
in spite of recent availability of the immunotherapy options in the 
second line setting [10]. After platinum based chemotherapy, median 
overall survival remains poor and therefore effective options are 
still needed in this patient group. However, this patient group is 
usually elderly with multiple co-morbidities, which has resulted 
in the lack of large phase III trials in the second line setting using 
chemotherapeutic options. 
There has been limited number of randomised phase III/ II trials 
showing a meaningful benefit of second line treatment compared 
with other active treatment [6,7,9-12]. 
Our study achieved its primary endpoint and is the second phase II 
study confirming the safety profile of the Cabazitaxel in the second 
line treatment [13]. The median OS in our study of 5.8 months for 
Cabazitaxel and 7.5 months for Paclitaxel (BSC) were similar to 
those observed in other clinical trials [13,14]. 
Limitations of the study were mainly the small numbers of patients 
being recruited and the high numbers of patients from both arms 
not being evaluable for response due to toxicity of treatment, early 
progression and withdrawal from the study. 
In spite of newer options such as monoclonal antibodies against 
programmed death 1 (PD-1) and it’s ligands (PD-L1 and PD-L2) 
being available in the second line setting, we have to remember 
that there are group of patients where immunotherapy may not be 
an option of treatment due to co-existing condition. This phase II 
study confirms safety profile of Cabazitaxel in second line treatment 
of urothelial carcinoma following platinum based treatment in this 
patient population. 
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